Project Grant K43TW011125

This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to integrate single-cell omics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping to characterize the immune response to tuberculosis (TB). The $517,185 award, with a performance period from Aug 1, 2024 to Jun 30, 2026, will fund the generation of multi-omic data from 225...

This five-year, $813,838 project grant from the National Institute of Allergy and Infectious Diseases will fund research into the genetic and hormonal mechanisms underlying sex differences in tuberculosis (TB) and TB-HIV coinfection. The Johns Hopkins University will investigate how X chromosome complement and sex steroid hormones impact TB pathogenesis using cellular models, animal studies, and human samples. Researchers will utilize a novel four core genotype mouse model to differentiate the...

This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,817,044 in funding to the University of Massachusetts Medical School (UMass Medical) to conduct research on the systems genetics of tuberculosis. The grant supports a multifaceted research program that aims to understand the complex biological determinants of tuberculosis infection outcomes, leveraging...

This federal Project Grant award of $766,877 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund a pragmatic, randomized controlled trial to determine the efficacy of therapeutic drug monitoring (TDM) in preventing premature discontinuation of the antibiotic linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The study will enroll 280 RR-TB patients in South Africa and randomize them to receive...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize metabolic profiles and outcomes among tuberculosis (TB) patients in Tanzania. The $201,549 award to the Medical University of South Carolina will fund a 5-year study with the following objectives: Measure and describe metabolic markers and TB severity at the time of TB diagnosis, testing...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility test (termed TRE-DST) for tuberculosis (TB). The TRE-DST system utilizes novel fluorescent trehalose probes to detect live Mycobacterium tuberculosis and determine drug resistance, addressing limitations of current diagnostic methods. Key...

This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...